Navigation Links
AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer

cinomas carrying the erlotinib-resistant mutation EGFR L858R/T790M. These in vivo results suggest that AV-412 may exert potent clinical activity against non-small cell lung cancer tumors harboring EGFR L858R or EGFR L858R/T790M mutations.

About AV-412

AV-412 is a next generation oral tyrosine kinase inhibitor of EGFR/HER2 that could potentially treat patients with solid tumors. In preclinical studies, AV-412 has shown excellent activity in various tumor models, has a toxicity profile similar to other molecules in its class, and has shown preclinical activity against tumor cells that are resistant to first-generation tyrosine kinase inhibitors. The targets of AV-412 have been implicated in many significant human cancers including non-small cell lung cancer, metastatic breast cancer, pancreatic cancer, head and neck cancer and hormone refractory prostate cancer. AVEO's proprietary Human Response Prediction(TM) Platform offers an opportunity to exploit AV-412's unique characteristics and will provide further insight into potential clinical settings, tumor subtypes and responsive patient populations. AVEO acquired worldwide rights outside of Asia to AV-412 from Mitsubishi Pharma Corporation. For more information on the AV-412 clinical trial, visit www.clinicaltrials.gov and search using the keyword AV-412.

About AVEO

AVEO is a private biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. The company utilizes its proprietary, genetically-defined cancer models for the identification and validation of novel cancer targets, and has begun to build an impressive portfolio of drug discovery and development programs around these high-value targets. AVEO also uses its Human Response Prediction(TM) Platform to identify genetic profiles that correspond with patient responsiveness. AVEO expects to commence Phase 2 clinical studies by Q3-2007 for AV-951, its oral, second-generation VEGF receptor inhibit
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:10/22/2014)... , Oct. 22, 2014  AcelRx Pharmaceuticals, ... that results from the  IAP310 study have been ... (RAPM), a peer-reviewed journal with broad, multidisciplinary ... trial evaluating the safety and efficacy of Zalviso, ... system (SSTS), for the treatment of post-operative pain ...
(Date:10/22/2014)... , Oct. 22, 2014   Foundation ... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ) ... genomic profiling to biopharmaceutical companies conducting clinical trials in ... the terms of the collaboration, Foundation Medicine will license ... Foundation Medicine,s FoundationOne® assay at the WuXi Genome Center ...
(Date:10/20/2014)... , Oct. 20, 2014  Indianapolis interventional medical ... Toronto -based 3D visualization leader ... of Neurological Surgeons Annual Meeting that they have ... brain surgery. The collaboration is the first of ... to improve patient outcomes. NICO,s BrainPath® interventional access ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
... 14, 2012 Ingenol mebutate was proven efficacious ... Today, the New England Journal of Medicine (NEJM) ... Phase III clinical trials for ingenol mebutate gel, demonstrating that ... of actinic keratoses (AKs) on the trunk-extremities or face-scalp with ...
... DIEGO, March 14, 2012 Arena Pharmaceuticals, Inc. (NASDAQ: ... the fourth quarter and full year ended December 31, ... the potential to be an important option for physicians ... lose weight and improve their overall cardiometabolic health," said ...
Cached Medicine Technology:New England Journal of Medicine Article Reviews the Benefits of Ingenol Mebutate in Field Treatment of Actinic Keratoses 2New England Journal of Medicine Article Reviews the Benefits of Ingenol Mebutate in Field Treatment of Actinic Keratoses 3New England Journal of Medicine Article Reviews the Benefits of Ingenol Mebutate in Field Treatment of Actinic Keratoses 4New England Journal of Medicine Article Reviews the Benefits of Ingenol Mebutate in Field Treatment of Actinic Keratoses 5Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 2Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 3Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 4Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 5Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 6Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 7Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 8
(Date:10/22/2014)... Tara Haelle HealthDay ... Binge drinking among young adult men may lead to increased ... drinking didn,t cause a similar rise in blood pressure for ... In fact, when young adult women drank lightly or moderately, ... the study found. "This finding parallels studies in older ...
(Date:10/22/2014)... Dennis Thompson HealthDay ... U.S. health officials on Monday officially tightened guidelines for health ... no skin exposure and use of a respirator at all ... decided to issue the tougher rules after two Dallas nurses ... in the United States, Liberian national Thomas Eric Duncan. Nina ...
(Date:10/20/2014)... October 20, 2014 With a mere ... Charlie Crist made a brief fundraising stop at the ... Thursday. , Fresh from a debate last night with ... the stage for the first seven minutes because Crist ... governor described the incident in one word: "weird." , ...
(Date:10/20/2014)... NY (PRWEB) October 20, 2014 ... non-profit organization that helps New Yorkers living with ... changes toward health, housing, recovery and self-sufficiency. Each ... transformed the local community through their tireless efforts. ... Marc Shapses , has been selected as ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 hc1.com ... a secure cloud solution that enables healthcare organizations ... the ultimate healthcare-specific customer relationship management (“CRM”) solution. ... the unique needs of the healthcare industry, the ... for providers and patients by combining healthcare CRM, ...
Breaking Medicine News(10 mins):Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2
... on the internet do not contain the ingredients they claim. ... over the internet. These are findings of Dr. Mark Baron, ... see what each contained. The study is published today in ... is clear that consumers are buying products that they think ...
... CAA multi-institutional team headed by Ursula Bellugi, professor and ... Salk Institute for Biological Studies, has been awarded a ... of Child Health and Human Development (NICHD) to link ... basis using Williams syndrome as a model. ...
... Kathleen Doheny HealthDay Reporter , THURSDAY, May ... in Afghanistan or Iraq face a higher risk of ... Researchers from the Uniformed Services University of the Health ... whose parents were on active duty between 2007 and ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, ... the chest after an road accident has been able to ... take some assisted steps on a treadmill, thanks to electrical ... called epidural spinal cord stimulation -- mimics signals the brain ...
... effect of impairing the patient,s immune system. This can ... especially since bacteria, like Staphylococcus aureus , are ... Central,s open access journal Annals of Clinical Microbiology ... plants against bacterial and fungal infections in the mouths ...
... University of California, Los Angeles (UCLA), the California Institute ... used a stimulating electrode array to assist a paralyzed ... and, over time, to regain voluntary movements of his ... researchers have found, stimulate the spinal cord,s own neural ...
Cached Medicine News:Health News:Buying 'legal highs' from the Internet is a risky business 2Health News:NIH awards Salk Institute $5.5 million grant to study Williams syndrome 2Health News:Kids of Deployed Parents May Face Mental Health Risks 2Health News:Kids of Deployed Parents May Face Mental Health Risks 3Health News:Spinal Stimulation Helps Paralyzed Man Regain Movement 2Health News:Spinal Stimulation Helps Paralyzed Man Regain Movement 3Health News:Spinal Stimulation Helps Paralyzed Man Regain Movement 4Health News:Herbal remedies offer hope as the new antibiotics 2Health News:Caltech research helps paraplegic man stand and move legs voluntarily 2Health News:Caltech research helps paraplegic man stand and move legs voluntarily 3Health News:Caltech research helps paraplegic man stand and move legs voluntarily 4Health News:Caltech research helps paraplegic man stand and move legs voluntarily 5
Pre-Loaded with a Stylet., ,Available Cuffed or Uncuffed, pre-loaded with a stylet to facilitate quick intubations....
... volume tapered, low pressure cuff., ,Sheridan ... today's healthcare professionals., High level of tactile ... allows the tube to soften at body ... gently cupped to minimize trauma during intubation ...
Adult (ICU) Tracheal Tubes with Micro-thin-walled cuffs....
Indications For Usage: ,Microlaryngeal surgery....
Medicine Products: